Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond

Antonia, 2017, Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N. Engl. J. Med., 377, 1919, 10.1056/NEJMoa1709937 Lala, 2020, A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation, Eur. J. Cancer, 131, 68, 10.1016/j.ejca.2020.02.016 Garassino, 2018, Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study, Lancet Oncol., 19, 521, 10.1016/S1470-2045(18)30144-X Antonia, 2019, Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC, J. Thorac. Oncol., 14, 1794, 10.1016/j.jtho.2019.06.010 Antonia, 2016, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, Lancet Oncol., 17, 299, 10.1016/S1470-2045(15)00544-6 Fujiwara, 2019, Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors, Cancer Sci., 110, 1715, 10.1111/cas.14003 Rizvi, 2020, Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial, JAMA Oncol., 6, 661, 10.1001/jamaoncol.2020.0237 Paz-Ares, 2019, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial, Lancet, 394, 1929, 10.1016/S0140-6736(19)32222-6 WHO, 2020 NICE, 2020